Anti-miRNA103/107 encapsulated in trasnferrin-conjugated lipid nanoparticles crosses the blood-brain barrier and reduces brain ischemic damage.

Abstract

MicroRNA(miRNA), by post-transcriptionally regulating the expression of genes involved in stroke response, represent important effectors in stroke pathophysiology. Recently, the 103/107 miRNA family emerged as possible therapeutic target in stroke, as it controls the expression of sodium calcium exchanger 1, a plasmamembrane transporter that plays a fundamental role in stroke pathophysiology. Although the neuroprotective properties of this and other miRNAs are promising, several pharmacokinetic drawbacks remain to be faced for the development of a translatable therapy based on small RNAs in CNS diseases. In the present study, to overcome these limitations, the anti-miRNA103/107 was encapsulated in specific preparations of lipid nanoparticles(LNPs), and their effectiveness was evaluated both in an in vitro model of hypoxia represented by primary neuronal cortical cultures exposed to Oxygen and Glucose Deprivation followed by reoxygenation, and in an in vivo model of stroke obtained in rats exposed to transient occlusion of the Middle Cerebral Artery. The results of the present study demonstrated that the encapsulation of anti-miRNA103/107 in transferrin-conjugated PEG-stabilized lipid nanoparticles allowed the blood-brain barrier crossing and significantly reduce brain ischemic damage. The present achievements pave the way for the exploitation of a systemic intravenous miRNA delivery strategy in stroke therapy.